head and neck cancer 1016O PHASE 2, RANDOMIZED TRIAL (CONCERT-2) OF PANITUMUMAB (PMAB) PLUS RADIOTHERAPY (PRT) COMPARED WITH CHEMORADIOTHERAPY (CRT) IN PATIENTS (PTS) WITH UNRESECTED, LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
نویسندگان
چکیده
J. Giralt1, J.M. Trigo2, S. Nuyts3, E.M. Ozsahin4, K. Skladowski5, G. Hatoum6, J. Daisne7, A. Zhang8, K. Oliner9, A. Vanderwalde10 Radiation Oncology, Vall d`Hebron University Hospital, Barcelona, SPAIN, Medical Oncology, Hospital Universitario Virgen de la Victoria, Malaga, SPAIN, Radiation Oncology, University Hospitals Leuven, Leuven, BELGIUM, Radiation Oncology, Lausanne University Medical Center (Centre Hospitalier Universitaire Vaudois), Lausanne, SWITZERLAND, Radiation Oncology, Centrum Onkologii Instytut M. Sklodowskiej-Curie, Gliwice, POLAND, Clinical Biomedical Sciences, Florida Atlantic University, Lake Worth, FL, UNITED STATES OF AMERICA, Radiation Oncology, Clinique & Maternité Ste-Elisabeth, Namur, BELGIUM, Global Biostatistics, Amgen, Thousand Oaks, CA, UNITED STATES OF AMERICA, Medical Sciences Ivd, Amgen, Thousand Oaks, CA, UNITED STATES OF AMERICA, Oncology Therapeutics, Amgen, Thousand Oaks, CA, UNITED STATES OF AMERICA
منابع مشابه
A Review on the Efficacy of Chemotherapy in Locally Advanced Head and Neck Cancers
Background and Aims: Chemotherapy is utilized as a part of combined-modality programs to achieve organ preservation and improve survival in patients with locally advanced head and neck cancer. Combinedmodality protocols can be used in three forms: a) neoadjuvant induction chemotherapy before definitive surgery or radiotherapy; b) concomitant chemoradiotherapy; and c) sequential therapy consisti...
متن کاملDOES HYPERFRACTIONATED RADIOTHERAPY CHANGE THE OUTCOME OF HEAD AND NECK CANCER? A TRIAL COMPARING CONVENTIONAL WITH HYPERFRACTIONATED RADIOTHERAPY
The optimal fractionation schedule for radiotherapy of head and neck cancer has been controversial. The objective of this randomized trial was to test the efficacy of hyperfractionation vs. standard fractionation. Patients with squamous cell carcinoma of head and neck organs were randomly assigned to receive radiotherapy delivered with A) standard fractionation at 2 Gy/fraction/day, 5 days...
متن کاملNeoadjuvant chemotherapy or chemoradiotherapy in head and neck cancer.
The multidisciplinary approach to treating squamous cell carcinoma of the head and neck is complex and evolving. Chemotherapy is increasingly being incorporated into the treatment of squamous cell carcinoma of the head and neck. Previously, radiotherapy following surgery was the standard approach to the treatment of loco regionally advanced resectable disease. Data from randomized trials have c...
متن کاملAfatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial
BACKGROUND Over 50% of patients with head and neck squamous cell carcinoma (HNSCC) present with locoregionally advanced disease. Those at intermediate-to-high risk of recurrence after definitive therapy exhibit advanced disease based on tumour size or lymph node involvement, non-oropharynx primary sites, human papillomavirus (HPV)-negative oropharyngeal cancer, or HPV-positive oropharynx cancer...
متن کاملPhase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck.
BACKGROUND Panitumumab has the potential to improve the therapeutic ratio of concurrent chemoradiotherapy for squamous cell carcinoma of the head and neck (SCCHN). PATIENTS AND METHODS This phase I dose-finding study investigated escalating doses of paclitaxel (Taxol) given concurrently with panitumumab, carboplatin and intensity-modulated radiotherapy (IMRT) for stage III-IVB SCCHN. Untreate...
متن کامل